HuGE Literature Finder
Records 1-5
Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Current medical science 2021 Feb 41 (1): 118-126. Chang Xiao-Na, Shang Fu-Mei, Jiang Hong-Yu, Chen Chen, Zhao Zhe-Yan, Deng Sheng-He, Fan Jun, Dong Xiao-Chuan, Yang Ming, Li Yan, Cai Kai-Lin, Liu Li, Liu Hong-Li, Nie X |
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
International journal of cancer 2021 Feb 148 (3): 682-691. Assenat Eric, Mineur Laurent, Mollevi Caroline, Lopez-Crapez Evelyne, Lombard-Bohas Catherine, Samalin Emmanuelle, Portales Fabienne, Walter Thomas, de Forges Hélène, Dupuy Marie, Boissière-Michot Florence, Ho-Pun-Cheung Alexandre, Ychou Marc, Mazard Thiba |
Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.
Journal of thrombosis and haemostasis : JTH 2015 Jun 13 (6): 998-1003. Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes C |
Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study.
Thrombosis research 2014 Jan 133 (1): 48-51. Corrales-Rodriguez Luis, Soulières Denis, Weng Xiaoduan, Tehfe Mustapha, Florescu Marie, Blais Norma |
Biomolecular, biochemical, and radiologic evaluation and safety of chemotherapy with bevacizumab in treatment of patients affected by mCRC.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e14140. Rossi L, Veltri E, Colonna M, Zoratto F, Vari S, Mottolese M, Di Seri M, Romiti A, Longo F, Giannarelli D, Tomao |
- Page last reviewed:Oct 1, 2020
- Page last updated:Apr 08, 2021
- Content source: